StonvexLoading…
StonvexStonvexStonvexCore line items from CSCO's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-01-24 | Q4 2025 2025-10-25 | Annual 2025 2025-07-26 | Q2 2025 2025-04-26 |
|---|---|---|---|---|
Revenue | $30.23B | $14.88B | $56.65B | $41.98B |
Operating Income | $7.14B | $3.36B | $11.76B | $8.67B |
Net Income | $6.04B | $2.86B | $10.18B | $7.63B |
EPS (Diluted) | $1.51 | $0.72 | $2.55 | $1.91 |
Total Assets | $123.37B | $121.10B | $122.29B | $119.78B |
Total Liabilities | $75.65B | $74.23B | $75.45B | $73.85B |
Cash & Equivalents | $7.46B | $8.40B | $8.35B | $8.16B |
Free Cash Flow OCF − CapEx | $4.43B | $2.89B | $13.29B | $9.27B |
Shares Outstanding | 3.95B | 3.94B | 3.96B | 3.96B |